Squarepoint’s Intellia Therapeutics NTLA Stock Holding History

Squarepoint’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-21,800	Closed	-$376K	–	4690
2025 Q3	$376K	Buy	+21,800	New	+$268K	﹤0.01%	3487

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Squarepoint's NTLA Position: Q2 2026 in Review

Squarepoint sold out of Intellia Therapeutics (NTLA) in Q2 2026, closing a stake of 209,983 shares — an estimated $2.69M sold.

Squarepoint first reported a position in NTLA in Q4 2017 and held it in 24 quarters. The position peaked at $13.1M in Q3 2021. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Squarepoint reported no remaining Intellia Therapeutics position as of Q2 2026 after selling out during the quarter.
Squarepoint sold 209,983 Intellia Therapeutics shares in Q2 2026, an estimated $2.69M.
Squarepoint first reported a position in Intellia Therapeutics in Q4 2017 and held it in 24 quarters.
Squarepoint's Intellia Therapeutics position peaked at $13.1M in Q3 2021.
328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.